|
US5464758A
(en)
|
1993-06-14 |
1995-11-07 |
Gossen; Manfred |
Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
|
|
US5658785A
(en)
|
1994-06-06 |
1997-08-19 |
Children's Hospital, Inc. |
Adeno-associated virus materials and methods
|
|
US5985846A
(en)
|
1995-06-07 |
1999-11-16 |
Baylor College Of Medicine |
Gene therapy for muscular dystrophy
|
|
US7232899B2
(en)
|
1996-09-25 |
2007-06-19 |
The Scripps Research Institute |
Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
|
|
WO1998054345A1
(en)
|
1997-05-30 |
1998-12-03 |
Baxter International Inc. |
Mini-adenoviral vector
|
|
AU770005B2
(en)
|
1998-04-15 |
2004-02-12 |
Research Foundation Of The State University Of New York, The |
Selective regulation of adenovirus production
|
|
US5981225A
(en)
|
1998-04-16 |
1999-11-09 |
Baylor College Of Medicine |
Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
|
|
US5989910A
(en)
|
1998-08-03 |
1999-11-23 |
University Of Lausanne |
Potent genetic switch allowing regulated gene expression in eukaryotic cells
|
|
US6423544B1
(en)
|
1998-12-31 |
2002-07-23 |
Chiron Corporation |
Compositions and methods for producing recombinant virions
|
|
MY123548A
(en)
|
1999-11-08 |
2006-05-31 |
Shell Int Research |
Method and system for suppressing and controlling slug flow in a multi-phase fluid stream
|
|
DE19955558C2
(de)
|
1999-11-18 |
2003-03-20 |
Stefan Kochanek |
Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
|
|
US6558948B1
(en)
|
1999-11-23 |
2003-05-06 |
Stefan Kochanek |
Permanent amniocytic cell line, its production and use for the production of gene transfer vectors
|
|
EP1362096B1
(de)
|
2001-02-21 |
2009-08-19 |
CEVEC Pharmaceuticals GmbH |
Pigmentepithelzelle des auges, ihre herstellung und verwendung in der therapie einer augen- oder zns-erkrankung
|
|
CA2485939C
(en)
|
2002-05-29 |
2013-10-29 |
Regeneron Pharmaceuticals, Inc. |
Inducible eukaryotic expression system
|
|
US8673589B2
(en)
|
2002-05-29 |
2014-03-18 |
Regeneron Pharmaceuticals, Inc. |
Inducible eukaryotic expression system
|
|
EP1743041B1
(en)
|
2004-05-03 |
2012-06-27 |
Stefan Kochanek |
Modified viral vector particles
|
|
DE102005054628A1
(de)
|
2005-11-16 |
2007-05-24 |
Cevec Pharmaceuticals Gmbh |
Verfahren zur Herstellung von permanenten humanen Zelllinien
|
|
WO2007084773A2
(en)
*
|
2006-01-20 |
2007-07-26 |
University Of North Carolina At Chapel Hill |
Enhanced production of infectious parvovirus vectors in insect cells
|
|
EP2431469A3
(en)
|
2006-05-15 |
2012-05-30 |
Paratek Pharmaceuticals, Inc. |
Methods of regulating expression of genes or of gene products using substituted tetracycline compounds
|
|
WO2008151219A1
(en)
|
2007-06-04 |
2008-12-11 |
Regeneron Pharmaceuticals, Inc. |
Enhanced expression and stability regions
|
|
US8852926B2
(en)
|
2007-10-25 |
2014-10-07 |
Board Of Trustees Of Southern Illinois University |
Genetic selection system for identification of MicroRNA target genes
|
|
DE102009003439A1
(de)
|
2009-02-05 |
2010-08-26 |
Cevec Pharmaceuticals Gmbh |
Neue permanente humane Zelllinie
|
|
WO2010138263A2
(en)
*
|
2009-05-28 |
2010-12-02 |
University Of Massachusetts |
Novel aav 's and uses thereof
|
|
US20130023033A1
(en)
|
2010-03-29 |
2013-01-24 |
The Trustees Of The University Of Pennsylvania |
Pharmacologically induced transgene ablation system
|
|
US8927514B2
(en)
|
2010-04-30 |
2015-01-06 |
City Of Hope |
Recombinant adeno-associated vectors for targeted treatment
|
|
US9839696B2
(en)
|
2010-04-30 |
2017-12-12 |
City Of Hope |
Recombinant adeno-associated vectors for targeted treatment
|
|
SG187863A1
(en)
|
2010-08-16 |
2013-03-28 |
Cevec Pharmaceuticals Gmbh |
Permanent human amniocyte cell lines for producing influenza viruses
|
|
EP2662451A1
(en)
|
2012-05-07 |
2013-11-13 |
Stefan Kochanek |
Nucleic acid construct and use of the same
|
|
EP2711428A1
(en)
|
2012-09-21 |
2014-03-26 |
Lonza Biologics plc. |
Site-specific integration
|
|
ES2698610T3
(es)
|
2013-08-06 |
2019-02-05 |
Lonza Biologics Plc |
Medios y métodos para la generación de células productoras de mamífero para la producción de proteínas recombinantes
|
|
GB201322798D0
(en)
|
2013-12-20 |
2014-02-05 |
Oxford Biomedica Ltd |
Production system
|
|
EP4410805A3
(en)
|
2014-03-18 |
2024-11-27 |
University of Massachusetts |
Raav-based compositions and methods for treating amyotrophic lateral sclerosis
|
|
KR102243243B1
(ko)
|
2014-10-23 |
2021-04-22 |
리제너론 파마슈티칼스 인코포레이티드 |
신규한 cho 통합 부위 및 이의 용도
|
|
EP3042952A1
(en)
|
2015-01-07 |
2016-07-13 |
CEVEC Pharmaceuticals GmbH |
O-glycan sialylated recombinant glycoproteins and cell lines for producing the same
|
|
TWI707951B
(zh)
|
2015-04-08 |
2020-10-21 |
美商健臻公司 |
過大腺相關載體之製造
|
|
EP3205719A1
(en)
|
2016-02-15 |
2017-08-16 |
CEVEC Pharmaceuticals GmbH |
Cell lines for producing recombinant glycoproteins with di-antennary n-glycans, methods using the same, and recombinant glycoproteins
|
|
GB201603577D0
(en)
|
2016-03-01 |
2016-04-13 |
Oxford Genetics Ltd |
Promoter
|
|
MX2018011928A
(es)
|
2016-03-30 |
2019-03-28 |
Spark Therapeutics Inc |
Linea celular para produccion de proteina recombinante y/o vector viral.
|
|
US11512144B2
(en)
|
2016-04-20 |
2022-11-29 |
Regeneran Pharmaceuticals, Inc. |
Compositions and methods for making antibodies based on use of an expression-enhancing loci
|
|
GB2549809C
(en)
|
2016-06-23 |
2022-11-30 |
Univ Oxford Innovation Ltd |
Vector
|
|
US20190171188A1
(en)
|
2016-08-10 |
2019-06-06 |
Lonza Inc. |
Biopharmaceutical Batch Recipe Review by Exception
|
|
JP7112414B2
(ja)
|
2017-02-08 |
2022-08-03 |
フリードリッヒ ミーシェー インスティトゥート フォー バイオメディカル リサーチ |
網膜神経節細胞中の遺伝子の特異的発現のためのプロモーターｓｙｎｐ８８
|
|
WO2018150269A1
(en)
|
2017-02-17 |
2018-08-23 |
Lonza Ltd. |
Multi-site specific integration cells for difficult to express proteins
|
|
WO2018150271A1
(en)
|
2017-02-17 |
2018-08-23 |
Lonza Ltd. |
Mammalian cells for producing adeno-associated viruses
|
|
KR20190129092A
(ko)
|
2017-03-17 |
2019-11-19 |
론자 리미티드 |
자동화된 배치 데이터 분석
|
|
JP7142643B2
(ja)
|
2017-03-22 |
2022-09-27 |
ウルトラジェニックス ファーマシューティカル インコーポレイテッド |
Ｈｄａｃ阻害剤またはｒｅｐタンパク質を伴う細胞培養方法
|
|
EP3382014A1
(en)
|
2017-03-29 |
2018-10-03 |
CEVEC Pharmaceuticals GmbH |
Recombinant glycoproteins with reduced antennary fucosylation
|
|
GB201705927D0
(en)
|
2017-04-12 |
2017-05-24 |
Oxford Genetics Ltd |
Vector
|
|
US10858631B2
(en)
|
2017-04-18 |
2020-12-08 |
Glaxosmithkline Intellectual Property Development Limited |
Methods for adeno-associated viral vector production
|
|
CN110892064A
(zh)
|
2017-07-25 |
2020-03-17 |
牛津遗传学有限公司 |
腺病毒载体
|
|
EP3441471A1
(en)
|
2017-08-08 |
2019-02-13 |
CEVEC Pharmaceuticals GmbH |
Use of constitutively active variants of growth factor receptors as selection makers for the generation of stable producer cell lines
|
|
EP3456822A1
(en)
|
2017-09-19 |
2019-03-20 |
CEVEC Pharmaceuticals GmbH |
Inducible aav rep genes
|
|
WO2019073059A1
(en)
|
2017-10-12 |
2019-04-18 |
Freeline Therapeutics Limited |
ADENOVIRAL AUXILIARY VIRUSES WITH DEFECTIVE CYCLE LIFE, PRODUCTION AND USE FOR THE PRODUCTION OF RAAV
|
|
JP7274225B2
(ja)
|
2017-10-25 |
2023-05-16 |
ノイスコム アーゲー |
真核細胞系統
|
|
IL275462B2
(en)
|
2017-12-22 |
2026-01-01 |
Genentech Inc |
Targeted integration of nucleic acids
|
|
GB201800903D0
(en)
|
2018-01-19 |
2018-03-07 |
Oxford Genetics Ltd |
Vectors
|
|
WO2019157239A1
(en)
|
2018-02-08 |
2019-08-15 |
David Kiewlich |
Plasmid vectors for expression of large nucleic acid transgenes
|
|
GB201802122D0
(en)
|
2018-02-09 |
2018-03-28 |
Univ Oxford Innovation Ltd |
Product and use
|
|
GB201814590D0
(en)
|
2018-09-07 |
2018-10-24 |
Oxford Biomedica Ltd |
Viral vector production system
|
|
EP3597172A1
(en)
|
2018-07-16 |
2020-01-22 |
Kao Germany GmbH |
Hair treatment composition
|
|
WO2020041454A1
(en)
|
2018-08-21 |
2020-02-27 |
Lonza Ltd |
A process for creating reference data for predicting concentrations of quality attributes
|
|
GB201814141D0
(en)
|
2018-08-30 |
2018-10-17 |
Univ Oxford Innovation Ltd |
Method and compositions for producing a virus
|
|
JP7549582B2
(ja)
|
2018-10-01 |
2024-09-11 |
ロンザ リミテッド |
予測可能かつ安定な導入遺伝子発現を有するｓｓｉ細胞および形成の方法
|
|
WO2020077411A1
(en)
|
2018-10-17 |
2020-04-23 |
Children's Medical Research Institute |
Nucleic acid molecules and methods for aav vector selection
|
|
GB201816919D0
(en)
|
2018-10-17 |
2018-11-28 |
Glaxosmithkline Ip Dev Ltd |
Adeno-associated viral vector producer cell lines
|
|
EP3870604B1
(en)
|
2018-10-26 |
2022-11-23 |
F. Hoffmann-La Roche AG |
Multispecific antibody screening method using recombinase mediated cassette exchange
|
|
KR20210108406A
(ko)
|
2018-12-21 |
2021-09-02 |
론자 워커스빌 아이엔씨. |
바이러스 벡터의 자동화된 생산
|
|
AU2019403279A1
(en)
|
2018-12-21 |
2021-07-01 |
Genentech, Inc. |
Targeted integration of nucleic acids
|
|
SG11202106217TA
(en)
*
|
2018-12-21 |
2021-07-29 |
Lonza Walkersville Inc |
Adeno-associated virus (aav) producer cell line and related methods
|
|
GB201901571D0
(en)
|
2019-02-05 |
2019-03-27 |
Oxford Genetics Ltd |
Inducible AAV sysyem
|
|
GB201902068D0
(en)
|
2019-02-14 |
2019-04-03 |
Cambridge Entpr Ltd |
Methods of reactivating proliferative capacity non-proliferative tissues
|
|
CN113544509A
(zh)
|
2019-03-08 |
2021-10-22 |
牛津遗传学有限公司 |
选择抗体的方法
|
|
AU2020270960B2
(en)
|
2019-04-12 |
2026-01-29 |
Ultragenyx Pharmaceutical Inc. |
Engineered producer cell lines and methods of making and using the same
|
|
CA3138576A1
(en)
|
2019-05-16 |
2020-11-19 |
Trustees Of Boston University |
Regulated synthetic gene expression systems
|
|
AU2020284255A1
(en)
|
2019-05-30 |
2022-01-06 |
Solid Biosciences Inc. |
Recombinant herpesvirales vector
|
|
KR20220118436A
(ko)
|
2019-12-19 |
2022-08-25 |
론자 워커스빌 아이엔씨. |
바이러스 벡터의 자동화된 생산
|
|
WO2021146591A2
(en)
|
2020-01-17 |
2021-07-22 |
Asklepios Biopharmaceutical, Inc. |
Recombinant aav production
|
|
MX2022009560A
(es)
|
2020-02-04 |
2022-09-09 |
Oxford Genetics Ltd |
Proceso de fabricacion de vectores virales adenoasociados.
|
|
GB202001484D0
(en)
|
2020-02-04 |
2020-03-18 |
Oxford Genetics Ltd |
DNA amplification method
|
|
JP2023518415A
(ja)
|
2020-03-19 |
2023-05-01 |
ウルトラジェニックス ファーマシューティカル インコーポレイテッド |
組換えａａｖにおいてｃａｐおよびｒｅｐ配列の逆パッケージングを低減するための組成物および方法
|
|
JP2023526348A
(ja)
|
2020-05-15 |
2023-06-21 |
アイヴェックスソル インコーポレイテッド |
細胞療法及び遺伝子療法のための安定したウイルスベクター産生細胞を産生するための組成物及び方法
|
|
CN113699147B
(zh)
|
2020-05-22 |
2023-06-09 |
深圳市深研生物科技有限公司 |
基于四环素和Cumate的共调控序列
|
|
US20230279427A1
(en)
|
2020-07-24 |
2023-09-07 |
Regents Of The University Of Minnesota |
Cell lines for recombinant aav production and aav-implemented protein production
|
|
WO2022038367A1
(en)
|
2020-08-21 |
2022-02-24 |
Oxford Genetics Limited |
Process for making a recombinant aav library
|
|
GB202013057D0
(en)
|
2020-08-21 |
2020-10-07 |
Oxford Genetics Ltd |
Method of making recombinant aavs
|
|
GB202013060D0
(en)
|
2020-08-21 |
2020-10-07 |
Oxford Genetics Ltd |
Cell line
|
|
EP4006141A1
(en)
|
2020-11-25 |
2022-06-01 |
CEVEC Pharmaceuticals GmbH |
Method for the production of aav
|
|
WO2022173944A1
(en)
|
2021-02-11 |
2022-08-18 |
Lonza Houston, Inc. |
Adeno-associated virus (aav) production
|
|
WO2022223954A1
(en)
|
2021-04-19 |
2022-10-27 |
Oxford Genetics Limited |
Dna amplification method using care elements
|
|
US20230257831A1
(en)
|
2021-09-01 |
2023-08-17 |
Oxford Genetics Limited |
Method for determining aav titre
|
|
MX2024004691A
(es)
|
2021-10-18 |
2024-05-23 |
Regeneron Pharma |
Transcripcion controlada de polinucleotidos.
|
|
CA3235566A1
(en)
|
2021-10-18 |
2023-04-27 |
Michael Goren |
Mammalian cells comprising integrated cas9 genes to produce stable integration sites, and mammalian cells comprising stable integration sites and other sites
|
|
WO2023173105A2
(en)
|
2022-03-10 |
2023-09-14 |
Saliogen Therapeutics, Inc. |
Tetracycline inducer/repressor system and simplified viral particle production
|